Who Paid My Doc
Oren Tessler
Plastic Surgery Gilbert, AZ Medical Doctor
NPI 1407111248 CMS profile 199216
3686 S Rome St, Gilbert, AZ 85297
General payments
$88,128
Research payments
$17,504
Ownership & investment interest
$0
Through program year 2025, Oren Tessler of Gilbert, AZ is reported in the CMS Open Payments database as having received $88,128 across 133 general payments and $17,504 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 96th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,827 | 14 | |
| 2025 | Research | $342 | 1 | |
| 2024 | General | $508 | 12 | |
| 2023 | General | $82,052 | 20 | |
| 2022 | General | $1,136 | 26 | |
| 2021 | General | $1,671 | 33 | |
| 2020 | General | $412 | 17 | |
| 2019 | General | $523 | 11 | |
| 2019 | Research | $17,162 | 3 |
Beside peers
- Oren Tessler
- Plastic Surgery median
- Middle half of Plastic Surgery
- National median
In program year 2025, general payments to Oren Tessler were reported at $1,827. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.
Show as a table
| Year | Oren Tessler | Plastic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $523 | $371 | $122–$1,483 | $163 |
| 2020 | $412 | $158 | $52–$438 | $114 |
| 2021 | $1,671 | $249 | $87–$752 | $132 |
| 2022 | $1,136 | $274 | $102–$793 | $149 |
| 2023 | $82,052 | $299 | $113–$891 | $160 |
| 2024 | $508 | $361 | $124–$1,062 | $164 |
| 2025 | $1,827 | $379 | $138–$1,100 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
30
Drug cost
$247
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Cephalexin | Generic | 19 | $226 | |
| Oxycodone Hcl | Generic | 11 | $21 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 700 Part D prescribers listed as Plastic Surgery; they describe a distribution and say nothing about conduct.
Records
137 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Plastic Surgery in Arizona
Related records
Plastic Surgery in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Plastic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.